Neuropathic pain: exosomes remain a largely preclinical research avenue

A review dominated by preclinical models

Neuropathic pain is described in the abstract as a disabling chronic condition for which effective treatments remain limited. The researchers examined the mechanisms and therapeutic potential of exosomes derived from the stem cell secretome, primarily from mesenchymal stem cells.

The literature search, conducted according to the PRISMA 2020 guidelines, covers publications available through August 2026. The included studies examine models of chronic constriction injury, diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, among others.

Most report a reduction in pain-related behaviors. This preclinical finding should not be confused with a demonstrated reduction in pain experienced by patients.

Plausible mechanisms, not clinical proof

The observed effects were associated with a decrease in neuroinflammatory cytokines, inhibition of microglial activation and enhanced neurotrophic signaling. The review also describes modulation of the NF-κB and NLRP3 pathways.

These observations support biological plausibility: several processes associated with neuropathic pain appear to be altered in the models studied. However, they do not demonstrate that these changes would produce a clinical benefit in humans.

The human evidence remains insufficient

The pilot clinical study suggests a potential benefit and a favorable safety profile. However, the abstract does not specify its sample size, duration, comparator or the magnitude of the result. It therefore does not allow the benefit to be quantified or safety to be assessed precisely.

Overall methodological quality is described as moderate. Stem cell sources, exosome isolation methods, dosing strategies, administration routes and outcome measures differ across studies. This heterogeneity prevented a meta-analysis: the authors conducted a narrative synthesis.

What this review changes

It identifies a research avenue, not a treatment with established efficacy. The authors call for randomized clinical trials and standardized characterization of the vesicles to determine whether the preclinical findings can translate into benefits for patients.

What we can take away

Stem cell-derived exosomes represent a biologically plausible research avenue for neuropathic pain. Human data remain insufficient to conclude that they are clinically effective.